Medications for COVID-19 prevention and therapeutic approaches during early-stage infection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

It has been established to date, that we can counteract the COVID-19 pandemic, by expanding preventive measures and starting to use two widely available drugs. In addition to the WHO’s social protective factors against COVID-19 (to enhance prevention and to improve treatment in infected patients, by reducing a viral load), there may be the following measures: • daily 60-second oropharyngeal rinsing with a 0.5-1% hydrogen peroxide solution (do not swallow); after 10 minutes, oropharyngeal washing with warm water (this is not recommended for children younger than 16 years); • daily 4-fold oropharyngeal rinsing and nasopharyngeal washing with a 0.23% povidone-iodine solution for 15 seconds (do not swallow). The coronavirus in the oropharynx and nasopharynx can be inactivated using 2 readily available agents (hydrogen peroxide and povidone-iodine). These measures are recommended for medical personnel and people who are in lockdown or quarantine, are infected at an early stage, and have had close contact with patients with COVID-19. These are not recommended for severely ill patients who have already developed pulmonary manifestations.

Full Text

Restricted Access

About the authors

A. Andzhaparidze

Peoples’ Friendship University of Russia

Moscow

O. A Burgasova

Peoples’ Friendship University of Russia

Email: olgaburgasova@mail.ru
Moscow

References

  1. Щелканов М.Ю., Колобухина Л.В., Львов Д.К. Коронавирусы человека (Nidovirales, Coronaviridae): возросший уровень эпидемической опасности. Лечащий врач. 2013; 10: 49-54
  2. Kirk-Bayley J., Combes J., Sunkaraneni S. et al. The Use of Povidone Iodine Nasal Spray and Mouthwash During the Current COVID-19 Pandemic May Reduce Cross Infection and Protect Healthcare Workers (March 28, 2020). Available at SSRN: https://ssrn.com/abstract=3563092 or http://dx.doi.org/10.2139/ ssrn.3563092
  3. Kampf G., Todt D., Pfaender S. et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020; 104 (3): 246-51. doi: 10.1016/j.jhin.2020.01.022
  4. Siber G.R., Thakrar N., Yancey B.A. et al. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine. 1991; 9 (10): 735-40. doi: 10.1016/0264-410x(91)90289-i
  5. Amanna I.J., Raué H.P., Slifka M.K. Development of a new hydrogen peroxide-based vaccine platform. Nat Med. 2012; 18 (6): 974-9. DOI: 10.1038/ nm.2763
  6. Kareem Essam, Reham Mohsen, Eman Amin Ismail et al. In Vitro Preparation of H2O2 Inactivated Rabies Vaccine and Related Immunogenicity. Int J Pul & Res Sci. 2018; 3 (4): 555619. doi: 10.19080/IJOPRS.2018.03.555619
  7. Sneader W. Drug discovery: a history. New York Wiley, 2005; p. 68.
  8. Traore O., Fayard S.F., Laveran H. An in vitro evaluation of the activity of povidone-iodine against nosocomial bacterial strains. J Hosp Infect. 1996; 34: 217-22. doi: 10.1016/s0195-6701(96)90069-9
  9. Shimizu M., Okuzumi K., Yoneyama A. et al. In vitro antiseptic susceptibility of clinical isolates from nosocomial Infections. Dermatology. 2002; 204 (Suppl. 1): 21-7. doi: 10.1159/000057720
  10. Rikimaru T., Kondo M., Kondo S. et al. Bactericidal activities of povidone-iodine against Mycobacterium. Dermatology. 1997; 195 (Suppl. 2): 104-6. doi: 10.1159/000246041
  11. Wutzler P., Sauerbrei A., Klocking R. et al. Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. Antiviral Res. 2002; 54: 89-97. doi: 10.1016/s0166-3542(01)00213-3
  12. Kawana R., Kitamura T., Nakagomi O. et al. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatology. 1997; 195 (Suppl. 2): 29-35. doi: 10.1159/000246027
  13. Kariwa H., Fujii N., Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology. 2006; 212 (Suppl. 1): 119-23. doi: 10.1159/000089211
  14. Eggers M., Eickmann M., Kowalski K. et al. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. BMC Infect Dis. 2015; 15: 375. doi: 10.1186/s12879-015-1111-9
  15. Eggers M., Eickmann M., Zorn J. Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus ankara (MVA). Infect Dis Ther. 2015; 4: 491-501. doi: 10.1007/s40121-015-0091-9
  16. Committee for the Japanese Respiratory Society Guidelines in Management of Respiratory. Prevention of hospital-acquired pneumonia (strategies for prevention of hospital-acquired infections). Respirology. 2004; 9: S4850.
  17. Eggers M., Koburger-Janssen T., Eickman M. et al. In Vitro Bacterial and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens. Infect Dis Ther. 2018; 7: 249-59. doi: 10.1007/s40121-018-0200-7
  18. Madan P.D., Sequeira P.S., Shenoy K. et al. The effect of three mouthwashes on radiation-induced oral mucositis in patients with head and neck malignancies: a randomized control trial. J Cancer Res Ther. 2008; 4: 38. doi: 10.4103/09731482.39597
  19. Kanagalingam J., Feliciano R., Hah J.H. et al. Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections. Int J Clin Pract. 2015; 69 (11): 1247-56. doi: 10.1111/ijcp.12707

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Russkiy Vrach Publishing House